Fernández-Trujillo Sergio, Jiménez-Moreno María, Ríos Ángel, Martín-Doimeadios Rosa Del Carmen Rodríguez
Department of Analytical Chemistry and Food Technology, Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Avenida Carlos III s/n, 45071, Toledo, Spain.
Department of Analytical Chemistry and Food Technology, Faculty of Chemical Sciences and Technologies, University of Castilla-La Mancha, Avenida Camilo José Cela s/n, 13071, Ciudad Real, Spain.
Talanta. 2021 Aug 15;231:122370. doi: 10.1016/j.talanta.2021.122370. Epub 2021 Mar 30.
A simple method based on the use of inductively coupled plasma mass spectrometry in single particle mode (SP-ICP-MS) has been proposed, for the first time, for the study of platinum nanoparticles (PtNPs) in complex clinical matrices such as human urine and blood serum. Critical parameters for signal acquisition were optimized to achieve a correct and simultaneous sizing and counting (particle-based in particles L and mass-based in ng L) of 50 and 70 nm PtNPs. Different reagents, as tetramethylammonium hydroxide (TMAH) and/or Triton X-100, and concentrations have been tested to ensure an adequate stabilization and extraction of PtNPs. Finally, TMAH at 1% is demonstrated to be the best reagent to extract the NPs guaranteeing their integrity. No heating or any additional treatment was required, which allows sample preparation, and the overall process, to be simple and fast. Good precisions for size (2% RSD) and particle number and mass concentrations (<1% RSD), and limits of detection of 21.6 nm and 1.9 × 10 particles L were reported. The influence of matrix on the determination of PtNP sizes and number- and mass-based concentrations was evaluated. Particle sizes were in all cases in accordance with values determined by TEM or SEM, whereas recoveries of PtNPs in terms of concentration ranged between 92 and 101%. The stability of PtNP characteristics after 24 h was specifically studied in human urine spiked with PtNPs. Statistically significant differences were only reported for the particle number concentrations of 50 nm PtNPs in female urine samples. The present work will be relevant to understand the behaviour of PtNPs in body fluids and to take appropriate actions in future (pre)clinical trials.
首次提出了一种基于单颗粒模式电感耦合等离子体质谱法（SP-ICP-MS）的简单方法，用于研究复杂临床基质（如人尿液和血清）中的铂纳米颗粒（PtNP）。对信号采集的关键参数进行了优化，以实现对50和70 nm PtNP的正确同时尺寸测定和计数（基于颗粒数/L和基于质量/ng L）。测试了不同的试剂，如氢氧化四甲铵（TMAH）和/或Triton X-100及其浓度，以确保对PtNP进行充分的稳定化和提取。最后，证明1%的TMAH是提取NP并保证其完整性的最佳试剂。无需加热或任何额外处理，这使得样品制备和整个过程简单快速。报告了尺寸（相对标准偏差2%）、颗粒数和质量浓度（相对标准偏差<1%）的良好精密度，以及21.6 nm的检测限和1.9×10颗粒/L。评估了基质对PtNP尺寸以及基于颗粒数和质量的浓度测定的影响。在所有情况下，颗粒尺寸均与通过透射电子显微镜（TEM）或扫描电子显微镜（SEM）测定的值一致，而PtNP浓度的回收率在92%至101%之间。特别研究了在添加了PtNP的人尿液中24小时后PtNP特性的稳定性。仅在女性尿液样品中50 nm PtNP的颗粒数浓度方面报告了统计学上的显著差异。本研究对于了解PtNP在体液中的行为以及在未来的（前）临床试验中采取适当行动具有重要意义。
